FSN reference: CAPA21-006

Subject: Urgent Field Safety Notice Evone UPDATE (see blue text)

Date: 05-Jul-2021

For attention of hospital staff responsible for medical devices.

Contact details of local representative*
<For Benelux>: Please contact Ventinova directly via manufacturer information <For other countries> Please contact <include distributor details>

Urgent Field Safety Notice (FSN)
EVONE
Failure to start ventilation

1	Information on Affected Devices
1.1	**Device Type(s)***
	Evone is a mechanical ventilator for use in operating rooms and ICU environments in hospitals.
2	**Commercial name(s)**
	Evone
3	**Unique Device Identifier(s) (UDI-DI)**
	08718969590150
4	**Primary clinical purpose of device(s)***
	Evone is intended to be used for ventilation of patients requiring FCV or jet ventilation modes.
5	**Device Model/Catalogue/part number(s)***
	REF: 6000
6	**Software version**
	Not relevant
7.	**Affected serial or lot number range**
	All serial numbers starting with '20'
8	**Associated devices**
	Not relevant

Ventinova Medical B.V.
A Meerenakkerplein 7
5652 BJ Eindhoven
The Netherlands
T +31 (0)40 751 60 20
E info@ventinova.nl
I www.ventinovamedical.com
Chamber of Commerce 58307834
VAT NL8529.77.694.B01
IBAN NL71 RABO 0314885706
BIC RABONL2U

2	Reason for Field Safety Corrective Action (FSCA)*
2.1	**Description of the product problem***
	The device may fail to start ventilation when used with supply pressures (oxygen or air) above 5 bar. In situations where the supply pressure varies, the device may pass the start-up test and then fail to start ventilation.
2.2	**Hazard giving rise to the FSCA***
	The device provides an alarm. A failure to start ventilation may lead to a delay of the procedure as the procedure must be re-planned or completed using an alternative means of ventilation.
2.3	**Probability of problem arising**
	The chance of an event where the start-up test passes but the device cannot start ventilation is estimated as two or three times a month on the complete installed base.
2.4	**Predicted risk to patient/users**
	A delayed procedure or the application of an alternative means of ventilation may lead to some form of patient injury although in the majority of these cases, no injury is expected. Estimated is some form of serious injury in 1 out of 100 procedures.
2.5	**Further information to help characterise the problem**
	The device may fail the start-up check or may provide an alarm when starting ventilation.
2.6	**Background on Issue**
	Ventinova received two complaints indicating the described event. Further investigation showed the events were reproducible when using supply pressures (far) above 5 bar. Further testing of a range of devices showed the event was limited to specific serial numbers. Root cause analyses has been performed on Evone's design. This revealed a timing issue in opening and closing of gas channels. In Evone devices with a serial number starting with 20, a new batch of a specific part was used that appeared to be more sensitive to higher inlet pressures. The combination of the found timing issue and the (increased) sensitivity of the newest batch of this specific part let to risk of a failure of producing flow at the start of ventilation at higher inlet pressures.

Ventinova Medical B.V.
A Meerenakkerplein 7
5652 BJ Eindhoven
The Netherlands
T +31 (0)40 751 60 20
E info@ventinova.nl
I www.ventinovamedical.com
Chamber of Commerce 58307834
VAT NL8529.77.694.B01
IBAN NL71 RABO 0314885706
BIC RABONL2U

3	Type of Action to mitigate the risk*		
3.1	**Action To Be Taken by the User*** ☐ Identify Device ☐ Quarantine Device ☐ Return Device ☐ Destroy Device ☒ On-site device modification/inspection ☐ Follow patient management recommendations ☐ Take note of amendment/reinforcement of Instructions for Use (IFU) ☐ Other ☐ None **Perform mandatory update of your device to software version 2.10.0 in cooperation with your Ventinova contact person or distributor.**		
3.2	**By when should the action be completed?**	Before 30 August 2021	
3.3	**Is customer Reply Required? *** (If yes, form attached specifying deadline for return)		No
3.4	**Action Being Taken by the Manufacturer** Ventinova has released a software version 2.10.0 that solves the issue. Ventinova will update the installed base.		
3.5	**By when should the action be completed?**	Ventinova expects to finalize the update of all affected devices within 2 months.	
3.6	**Is the FSN required to be communicated to the patient /lay user?**		No

4	General Information	
4.1	**FSN Type**	Update
4.4	**Further advice or information already expected in follow-up FSN?**	No
4.7	**Manufacturer information**	
	See footer. For all correspondence, use support@ventinova.nl	
4.8	**The Competent (Regulatory) Authority of your country has been informed about this communication to customers.**	
4.9	**List of attachments/appendices:**	None
4.10	**Name/Signature**	Paul Theunissen, RA Manager 

Ventinova Medical B.V.
A Meerenakkerplein 7
5652 BJ Eindhoven
The Netherlands

T +31 (0)40 751 60 20
E info@ventinova.nl
I www.ventinovamedical.com

Chamber of Commerce 58307834
VAT NL8529.77.694.B01
IBAN NL71 RABO 0314885706
BIC RABONL2U

	Transmission of this Field Safety Notice
	This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate) Please transfer this notice to other organisations on which this action has an impact. (As appropriate) Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action. Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.

Ventinova Medical B.V.
A Meerenakkerplein 7
5652 BJ Eindhoven
The Netherlands
T +31 (0)40 751 60 20
E info@ventinova.nl
I www.ventinovamedical.com
Chamber of Commerce 58307834
VAT NL8529.77.694.B01
IBAN NL71 RABO 0314885706
BIC RABONL2U